At the highest dose ( 600mg ) , evacetrapib significantly inhibited CETP activity ( 91 % ) , increased HDL-C ( 87 % ) and apo AI ( 42 % ) , and decreased LDL-C ( 29 % ) and apo B ( 26 % ) relative to placebo .